Stock Scorecard



Stock Summary for Protagenic Therapeutics Inc (PTIX) - $3.48 as of 7/3/2025 8:37:06 AM EST

Total Score

9 out of 30

Safety Score

18 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for PTIX

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for PTIX

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for PTIX

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for PTIX

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for PTIX (18 out of 100)

Stock Price Rating (Max of 10) 3
Historical Stock Price Rating (Max of 10) 9
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 0
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 4
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for PTIX

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates INZY, TXNM, SVT, PTIX on Behalf of Shareholders - Inozyme Pharma ( NASDAQ:INZY ) , Protagenic Therapeutics ( NASDAQ:PTIX ) 5/27/2025 2:22:00 PM
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Inozyme Pharma, Inc. ( Nasdaq - INZY ) , TXNM Energy, Inc. ( NYSE - TXNM ) , Servotronics, Inc. ( NYSE American - SVT ) , Protagenic Therapeutics, Inc. ( Nasdaq - PTIX ) 5/27/2025 1:18:00 PM
Nasdaq Falls 100 Points; Home Depot Sales Top Views - Ekso Bionics Holdings ( NASDAQ:EKSO ) , BloomZ ( NASDAQ:BLMZ ) 5/20/2025 2:01:00 PM
Gold Gains Over 1%; Protagenic Therapeutics Shares Spike Higher - Archer Aviation ( NYSE:ACHR ) , DigiAsia ( NASDAQ:FAAS ) 5/19/2025 5:40:00 PM
Protagenic Therapeutics ( PTIX ) Stock Soars 240% On Phytanix Merger - Protagenic Therapeutics ( NASDAQ:PTIX ) 5/19/2025 4:09:00 PM
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Inozyme Pharma, Inc. ( Nasdaq - INZY ) , TXNM Energy, Inc. ( NYSE - TXNM ) , Servotronics, Inc. ( NYSE American - SVT ) , Protagenic Therapeutics, Inc. ( Nasdaq - PTIX ) 5/19/2025 2:18:00 PM
Dow Tumbles 200 Points; ZIM Integrated Shipping Services Posts Upbeat Earnings - Affimed ( NASDAQ:AFMD ) , Damon ( NASDAQ:DMN ) 5/19/2025 1:58:00 PM
Dow Tumbles 1,100 Points; US Economy Adds 228,000 Jobs In March - AIM ImmunoTech ( AMEX:AIM ) , Impact BioMedical ( AMEX:IBO ) 4/4/2025 1:53:00 PM
Dow Tumbles Over 1,100 Points; US Initial Jobless Claims Fall - American Rebel Holdings ( NASDAQ:AREB ) , Aldeyra Therapeutics ( NASDAQ:ALDX ) 4/3/2025 1:42:00 PM
Why Penguin Solutions Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - American Rebel Holdings ( NASDAQ:AREB ) , Aptevo Therapeutics ( NASDAQ:APVO ) 4/3/2025 9:27:00 AM

Financial Details for PTIX

Company Overview

Ticker PTIX
Company Name Protagenic Therapeutics Inc
Country USA
Description Protagenic Therapeutics, Inc., a preclinical biopharmaceutical company, is dedicated to the discovery and development of therapies to treat stress-related mood and neuropsychiatric disorders. The company is headquartered in New York, New York.
Sector Name TRADE & SERVICES
Industry Name SERVICES-BUSINESS SERVICES, NEC
Most Recent Quarter 3/31/2025
Next Earnings Date N/A

Stock Price History

Last Day Price 3.48
Price 4 Years Ago 77.56
Last Day Price Updated 7/3/2025 8:37:06 AM EST
Last Day Volume 235,045
Average Daily Volume 450,709
52-Week High 15.54
52-Week Low 2.35
Last Price to 52 Week Low 48.09%

Valuation Measures

Trailing PE N/A
Industry PE 83.12
Sector PE 50.29
5-Year Average PE -44.27
Free Cash Flow Ratio 3.45
Industry Free Cash Flow Ratio 48.41
Sector Free Cash Flow Ratio 63.01
Current Ratio Most Recent Quarter 0.86
Total Cash Per Share 1.01
Book Value Per Share Most Recent Quarter -0.16
Price to Book Ratio 1.61
Industry Price to Book Ratio 9.09
Sector Price to Book Ratio 10.94
Price to Sales Ratio Twelve Trailing Months 0.00
Industry Price to Sales Ratio Twelve Trailing Months 4.16
Sector Price to Sales Ratio Twelve Trailing Months 2.28
Analyst Buy Ratings N/A
Analyst Strong Buy Ratings N/A

Share Statistics

Total Shares Outstanding 868,410
Market Capitalization 3,022,067
Institutional Ownership 4.75%

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 5.30%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -10.50%
Reported EPS 12 Trailing Months -13.13
Reported EPS Past Year -2.75
Reported EPS Prior Year -1.89
Net Income Twelve Trailing Months -5,242,000
Net Income Past Year -5,525,000
Net Income Prior Year -5,000,000
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth -100.00%
Operating Margin Twelve Trailing Months 0.00%

Balance Sheet

Total Cash Most Recent Quarter 872,960
Total Cash Past Year 1,838,469
Total Cash Prior Year 1,287,893
Net Cash Position Most Recent Quarter 872,960
Net Cash Position Past Year 1,838,469
Long Term Debt Past Year 0
Long Term Debt Prior Year 150,591
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 0.00
Total Stockholder Equity Past Year 1,013,154
Total Stockholder Equity Prior Year 3,668,117
Total Stockholder Equity Most Recent Quarter -88,329

Free Cash Flow

Free Cash Flow Twelve Trailing Months -3,625,349
Free Cash Flow Per Share Twelve Trailing Months -4.17
Free Cash Flow Past Year -4,216,517
Free Cash Flow Prior Year -3,853,551

Options

Put/Call Ratio 0.00
Has Options False
Liquidity Rating None

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.09
MACD Signal -0.11
20-Day Bollinger Lower Band 2.51
20-Day Bollinger Middle Band 3.74
20-Day Bollinger Upper Band 4.97
Beta 0.38
RSI 46.45
50-Day SMA 17.47
150-Day SMA 0.00
200-Day SMA 30.18

System

Modified 7/3/2025 8:37:53 AM EST